

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Shunichi IKUTA et al.
Appl. No.: **NEW DIVISIONAL** Group:
Filed: January 22, 2004 Examiner:
For: NOVEL BICYCLIC COMPOUNDS

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 22, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).

10/258,817

U.S. Filing Date(s)

October 28, 2002

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 25-0120.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

By *Benoît Castel*
Reg. No. 35,041 for
Philip Dubois, Reg. No. 50,696

PD/maf
8002-1007-1

745 South 23rd Street
Arlington, Virginia 22202
(703) 521-2297

Enclosures: ☒ PTO-1449
☐ References
☐ Foreign Search Report
☐ Other:

Revised January 9, 2003

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Attorney Docket No.: 8002-1007-1	Application No.: NEW DIVISIONAL
	Applicant: Shunichi IKUTA et al.	
	Filing Date: January 22, 2004	Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)
	6,037,362	3/1/2000	Miyoshi et al.			
	6,187,809	2/1/2001	Miyoshi et al.			
	5,977,124	11/1/1999	Dow			
	4,338,333	7/1/1982	Ainsworth et al.			
	5,767,133	6/1/1998	Dow et al.			
	6,172,099	1/1/2001	Miyoshi et al.			
	5,859,044	1/1/1999	Dow et al.			
	4,816,457	3/1/1989	Baldwin et al.			
	5,541,197	7/1/1996	Fisher et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	97/25311	7/17/1997	PCT				
	96/35670	11/14/1996	PCT				
	0 455 006	11/1/1991	EUROPE				
	0 659 737	6/1/1995	EUROPE				
	0 171 702	2/1/1986	EUROPE				
	55-53262	4/1/1980	JAPAN				
	58-41860	3/1/1983	JAPAN				
	1 565 080	4/1/1980	UNITED KINGDOM				
	1 142 883	10/1/2001	EUROPE				
	1 238 973	9/1/2002	EUROPE				
	1 174 425	1/1/2002	EUROPE				
	8-165276	6/1/1996	JAPAN				
	24 29 253	1/1/1976	GERMANY				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Barrie C.C. Cantello et al., "BRL 35135," Drugs of the Future, V. 16, 1991, pp. 797-800.
	David C. Humber et al., "Disodium(R,R)-5-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243)," J. Med Chem., V. 35, 1992, pp. 3081-3084.

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* Abstract provided for the Examiner's convenience

maf